医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TOKUSHIMA, Japan

150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2^nd, 3^rd, or 4^th salvage of AML and the 1^st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm. The endpoint is CR rate for primary and the Overall Survival for secondary. DFP-10917 (Radgocitabine) was granted as Orphan Drug Designation (ODD) by the FDA in US.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230427006072/en/